Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	41859-67-0
Formula :	C₁₉H₂₀ClNO₄
M.W :	361.82
SMILES Code :	CC(C)(OC1=CC=C(CCNC(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O
Synonyms :	BM15075; Benzofibrate; Bezafibratum
MDL No. :	MFCD00078970
InChI Key :	IIBYAHWJQTYFKB-UHFFFAOYSA-N
Pubchem ID :	39042

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P264-P270-P301+P312+P330-P501

MDA-MB-231	10 μM	48 h	Bezafibrate inhibits PKCβII expression and reduces NMHC-IIA phosphorylation	PMC10031283
LM-MCF-7	10 μM	48 h	Bezafibrate inhibits PKCβII expression and reduces NMHC-IIA phosphorylation	PMC10031283
MC3T3-E1 cells	100 μM	7-28 days	Bezafibrate enhanced differentiation and mineralization of MC3T3-E1 cells, increasing mRNA expression of ALP, collagen I and osteocalcin	PMC4002510
MC3T3-E1 cells	1-1000 μM	24-72 h	Bezafibrate increased the viability and proliferation of MC3T3-E1 cells in a dose- and time-dependent manner	PMC4002510
MO3.13 cells	500 µM and 1000 µM	24 or 48 h	To evaluate the effect of sulfite on the viability of MO3.13 cells. Results showed that sulfite significantly decreased cell viability, and Bezafibrate (1 µM) prevented this effect after 24 h incubation.	PMC10296939
INS-1 832/13 β-cells	1–100 nM	5 minutes	To evaluate the effect of compounds on insulin secretion. Results showed that tazarotenic acid, efaproxiral, and bezafibrate significantly increased insulin secretion at nanomolar concentrations, with EC50 values of 5.73 nM, 14.2 nM, and 13.5 nM, respectively.	PMC8759729

BALB/c nude mice	Breast cancer metastasis model	Oral gavage	25 mg/kg	Once daily for 55 days	Bezafibrate inhibits breast cancer metastasis by suppressing PKCβII-mediated NMHC-IIA phosphorylation	PMC10031283
TallyHo mice	Early diabetes (ED) and late diabetes (LD) models	Dietary supplementation	0.5% (w/w)	8 weeks	Bezafibrate markedly reduced plasma lipid and glucose levels, accompanied by elevated insulin sensitivity index and glucose tolerance. Additionally, Bezafibrate increased islet area in the pancreas, improved energy expenditure and metabolic flexibility. In the liver, Bezafibrate ameliorated steatosis, modified lipid composition, increased mitochondrial mass, and reduced hepatic gluconeogenesis.	PMC5323884
Wistar rats	Sulfite-induced neuroinflammation and oxidative stress model	Oral	30 or 100 mg/kg	Once daily for 7 days	To evaluate the protective effects of Bezafibrate against sulfite-induced neuroinflammation and oxidative stress. Results showed that Bezafibrate mitigated sulfite-induced myelin disruption, neuroinflammation, and oxidative stress.	PMC10296939
Mice	Ndufs4 KO mouse model	Dietary administration	0.5% BEZ	Continuous administration from p25	BEZ significantly extended the survival of Ndufs4 KO mice and attenuated disease progression. Decreased oxidative stress and stunted growth were also observed.	PMC9294104

{[proInfo.proName]}

CAS No.: 41859-67-0

{[proInfo.proName]}

CAS No.: 41859-67-0

Alternative Products

Product Details of Bezafibrate

Safety of Bezafibrate

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02584504	Hypercholesterolemia	Phase 3	Completed	-	Japan ... More >> Investigational Site Number 392028 Ageo-Shi, Japan Investigational Site Number 392007 Chuo-Ku, Japan Investigational Site Number 392029 Chuo-Ku, Japan Investigational Site Number 392014 Fukui-Shi, Japan Investigational Site Number 392023 Hachioji-Shi, Japan Investigational Site Number 392013 Itoshima-Shi, Japan Investigational Site Number 392010 Kanazawa-Shi, Japan Investigational Site Number 392024 Kasuga-Shi, Japan Investigational Site Number 392004 Kawanishi-Shi, Japan Investigational Site Number 392015 Kitakyushu-Shi, Japan Investigational Site Number 392005 Komatsu-Shi, Japan Investigational Site Number 392032 Matsudo-Shi, Japan Investigational Site Number 392017 Matsumoto-Shi, Japan Investigational Site Number 392003 Mito-Shi, Japan Investigational Site Number 392018 Morioka-Shi, Japan Investigational Site Number 392009 Moriya-Shi, Japan Investigational Site Number 392006 Nagoya-Shi, Japan Investigational Site Number 392011 Nagoya-Shi, Japan Investigational Site Number 392019 Nagoya-Shi, Japan Investigational Site Number 392025 Nagoya-Shi, Japan Investigational Site Number 392027 Osaka-Shi, Japan Investigational Site Number 392030 Sakura-Shi, Japan Investigational Site Number 392016 Shinagawa-Ku, Japan Investigational Site Number 392001 Shinjuku-Ku, Japan Investigational Site Number 392008 Shinjuku-Ku, Japan Investigational Site Number 392012 Shizuoka-Shi, Japan Investigational Site Number 392002 Suita-Shi, Japan Investigational Site Number 392031 Suita-Shi, Japan Investigational Site Number 392020 Toyonaka-Shi, Japan Investigational Site Number 392022 Yao-Shi, Japan Less <<
NCT02584504	-		Completed	-	-
NCT03031821	Prostate Cancer ... More >> Metabolic Syndrome Less <<	Phase 3	Not yet recruiting	June 1, 2023	Canada, British Columbia ... More >> BC Cancer Agency - Vancouver Cancer Centre Not yet recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Bernie Eigl, MD 604-877-6000 bernie.eigl@bccancer.bc.ca Principal Investigator: Bernie Eigl, MD Less <<
NCT02984982	Hypercholesterolemia ... More >> Acute Coronary Syndrome Less <<	Phase 4	Completed	-	Japan ... More >> Investigational Site Number 392026 Bunkyoku-ku, Japan Investigational Site Number 392022 Chiyoda-ku, Japan Investigational Site Number 392032 Fujisawa-shi, Japan Investigational Site Number 392004 Fukui-shi, Japan Investigational Site Number 392007 Fukuoka-shi, Japan Investigational Site Number 392048 Fukuoka-shi, Japan Investigational Site Number 392008 Gifu-shi, Japan Investigational Site Number 392039 Hiroshima-shi, Japan Investigational Site Number 392028 Isehara-shi, Japan Investigational Site Number 392036 Itabashi-ku, Japan Investigational Site Number 392037 Itabashi-ku, Japan Investigational Site Number 392024 Izumisano-shi, Japan Investigational Site Number 392013 Izunokuni-shi, Japan Investigational Site Number 392020 Kawaguchi-shi, Japan Investigational Site Number 392041 Kisarazu-shi, Japan Investigational Site Number 392009 Kitakyushu-shi, Japan Investigational Site Number 392034 Kitakyushu-shi, Japan Investigational Site Number 392044 Kochi-shi, Japan Investigational Site Number 392002 Kumamoto-shi, Japan Investigational Site Number 392011 Kumamoto-shi, Japan Investigational Site Number 392003 Kurashiki-shi, Japan Investigational Site Number 392018 Matsuyama-shi, Japan Investigational Site Number 392021 Morioka-shi, Japan Investigational Site Number 392017 Nagakute-shi, Aichi, Japan Investigational Site Number 392047 Nagaoka-shi, Japan Investigational Site Number 392038 Nagoya-shi, Japan Investigational Site Number 392042 Nagoya-shi, Japan Investigational Site Number 392033 Okayama-shi, Japan Investigational Site Number 392006 Osaka-shi, Japan Investigational Site Number 392010 Osaka-shi, Japan Investigational Site Number 392045 Osaka-shi, Japan Investigational Site Number 392046 Osaka-shi, Japan Investigational Site Number 392015 Sagamihara-shi, Japan Investigational Site Number 392019 Sakai-shi, Japan Investigational Site Number 392035 Sapporo-shi, Japan Investigational Site Number 392001 Tenri-shi, Japan Investigational Site Number 392016 Toyoake-shi, Japan Investigational Site Number 392025 Tsukuba-shi, Japan Investigational Site Number 392040 Tsukuba-shi, Japan Investigational Site Number 392005 Wakayama-shi, Japan Investigational Site Number 392027 Yokohama-shi, Japan Investigational Site Number 392043 Yokohama-shi, Japan Less <<
NCT00506298	Type 2 Diabetes	Phase 2	Completed	-	Canada, British Columbia ... More >> Chilliwack, British Columbia, Canada Vancouver, British Columbia, Canada Canada, Manitoba Winnipeg, Manitoba, Canada Canada, Newfoundland and Labrador Bay Roberts, Newfoundland and Labrador, Canada Holyroad, Newfoundland and Labrador, Canada St. Johns, Newfoundland and Labrador, Canada Canada, Ontario Aylmer, Ontario, Canada Burlington, Ontario, Canada Collingwood, Ontario, Canada Corunna, Ontario, Canada Robarts Research Institute London, Ontario, Canada London, Ontario, Canada Newmarket, Ontario, Canada Sarnia, Ontario, Canada Sudbury, Ontario, Canada Toronto, Ontario, Canada Canada, Quebec Montreal, Quebec, Canada Canada, Saskatchewan Saskatoon, Saskatchewan, Canada Less <<
NCT01527318	Neutral Lipid Storage Disease	Phase 4	Completed	-	Netherlands ... More >> Maastricht University Medical Center Maastricht, Limburg, Netherlands, 6200MD Less <<
NCT02548832	Mixed Dyslipidemia	Phase 2	Unknown	July 2016	Mexico ... More >> Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara Recruiting Guadalajara, Jalisco, Mexico, 44340 Contact: Esperanza Martínez Abundis, PhD Science (33) 1058-5200 ext 34211 esperanzamartnezabundi@yahoo.com Less <<
NCT02481245	Bipolar Disorder\|Depressive Ep... More >>isode Less <<	PHASE2	UNKNOWN	2025-06-23	The Dauten Family Center for B... More >>ipolar Treatment Innovation at Massachusetts General Hospital, Boston, Massachusetts, 02114, United States Less <<
NCT00336167	Carnitine Palmitoyl Transferas... More >>e 2 Deficiency Less <<	Phase 3	Unknown	July 2007	France ... More >> Jean Paul Bonnefont Recruiting Paris, France, 75015 Contact: Jean-Paul Bonnefont, MD; PhD bonnefont@necker.fr Less <<
NCT03649269	Hypertriglyceridemia	Not Applicable	Completed	-	-
NCT01165060	X-linked Adrenoleukodystrophy\|... More >>Adrenomyeloneuropathy Less <<		COMPLETED	2025-08-11	Academisch Medisch Centrum, Am... More >>sterdam, NH, 1100 DD, Netherlands Less <<
NCT02701166	Primary Biliary Cholangitis ... More >> Primary Sclerosing Cholangitis Secondary Sclerosing Cholangitis Less <<	Phase 3	Unknown	April 2018	Netherlands ... More >> Academic Medical Center Recruiting Amsterdam, Netherlands Contact: Ulrich Beuers, prof. dr. +31205662422 u.h.beuers@amc.uva.nl Contact: Ruth Bolier +31205668701 a.r.bolier@amc.uva.nl Principal Investigator: Ulrich Beuers, prof. dr. Sub-Investigator: Elsemieke de Vries Vrije Universiteit Medisch Centrum Recruiting Amsterdam, Netherlands Contact: Karin van Nieuwkerk, dr. +31-20-4440613 cmj.vannieuwkerk@vumc.nl Contact: Ineke Jansen +31-20-4449455 a.jansen1@vumc.nl Universitair Medisch Centrum Groningen Recruiting Groningen, Netherlands Contact: Marleen de Vree, dr. +31-6-55256255 j.m.l.de.vree@umcg.nl Contact: Lyda Engelsman +31-50-3614996 a.f.engelsman@umcg.nl Leids Universitair Medisch Centrum Recruiting Leiden, Netherlands Contact: Bart van Hoek, prof. dr. +31-71-5263507 b.van_hoek@lumc.nl Contact: Lida Beneken Kolmer +31-71-5261188 a.beneken_kolmer@lumc.nl Maastricht Universitair Medisch Centrum Recruiting Maastricht, Netherlands Contact: Peter Jansen, prof. dr. +31-43-3876543 plm.jansen@maastrichtuniversity.nl Contact: Tine Horsten +31-43-3874436 t.horsten@mumc.nl Radboud Universitair Medisch Centrum Recruiting Nijmegen, Netherlands Contact: Joost Drenth, prof. dr. +31-24-3613999 joostphdrenth@cs.com Contact: Sonja Cuppen +31-24-3619190 researchunit.mdl@radboudumc.nl Erasmus Medisch Centrum Recruiting Rotterdam, Netherlands Contact: Henk van Buuren, dr. +31-10-7035942 h.vanbuuren@erasmusmc.nl Contact: Maren Harms +31-10-7038922 m.h.harms@erasmusmc.nl Universitair Medisch Centrum Utrecht Recruiting Utrecht, Netherlands Contact: Karel van Erpecum, dr. +31-88-7555555 k.j.vanerpecum@umcutrecht.nl Contact: Janneke van den Brink +31-88-7557973 j.vandenbrink@umcutrecht.nl Spain University of Barcelona Not yet recruiting Barcelona, Spain Contact: Albert Parés, dr. +34-93-2275753 pares@ub.edu Less <<
NCT00983788	Carnitine Palmitoyltransferase... More >> II Deficiency Very Long Chain Acyl Coa Dehydrogenase Deficiency Less <<	Phase 2	Completed	-	Denmark ... More >> Neuromusculare Research Unit, Rigshospitalet Copenhagen, Denmark, 2100 Less <<
NCT02398201	Mitochondrial Diseases	PHASE2	COMPLETED	2017-03-23	Clinical Research Facility, Ro... More >>yal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, NE1 4LP, United Kingdom Less <<
NCT02937012	Primary Biliary Cirrhosis	Phase 3	Recruiting	December 2019	Mexico ... More >> Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Recruiting Mexico City, Mexico, 14000 Contact: Edgardo Eric Lopez Mendez, MD (01)(55) 54870900 ext 2710 ericlopezmendez@yahoo.com.mx Contact: Sergio Gabriel Munoz Martinez, MD (01)(55) 54870900 ext 2710 sergio_sg@hotmail.com Principal Investigator: Edgardo Eric Lopez Martinez, MD Sub-Investigator: Sergio Gabriel Munoz Martinez, MD Sub-Investigator: Ignacio Garcia Juarez, MD Sub-Investigator: Ernesto Marquez Guillen, MD Sub-Investigator: Carlos Moctezuma Velazquez, MD Sub-Investigator: Alejandra Tepox Padron, MD Less <<
NCT02291796	Acute Myocardial Infarction	PHASE4	COMPLETED	2025-12-13	-
NCT01654731	PBC	Phase 3	Completed	-	France ... More >> Hepatology department - Hopital Saint Antoine Paris, France, 75012 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed